CURRICULUM VITAE EUROPEO

INFORMAZIONI PERSONALI

Nome	**AZZARITI AMALIA**
E-mail	**a.azzariti@oncologico.bari.it**
Nazionalità	Italiana

ESPERIENZE LAVORATIVE

2001 – 2013
IRCCS Istituto Tumori Giovanni Paolo II – Viale O. Flacco,65 – 70124 Bari Italia
Ricercatore - Dirigente chimico e tecnologo farmaceutico
Responsabile del Settore di Farmacologia Clinica e Preclinica

1996-2000
CNR – Centro di Studio sui Mitocondri e Metabolismo Energetico – Bari, Italia
Studente di Dottorato di ricerca in Biochimica e Biologia Molecolare
Attività sperimentale in Biochimica e Biologia Molecolare

1996
Life Sciences Department - East London University – London, UK
Ricercatore borsista
Attività sperimentale in Biochimica

1992-1995
CNR - Centro di Studio sui Mitocondri e Metabolismo Energetico – Bari, Italia
Ricercatore borsista
Attività sperimentale in Biochimica e Biologia Molecolare

TITOLI ACCADEMINI

1996-2000
Dottore di ricerca in Biochimica e Biologia Molecolare – Università di Bari, Italia

1992
Laurea in Chimica e tecnologia farmaceutica – Università di Bari, Bari, Italia

COMPETENZE

Esperienza nel coordinamento di studi preclinici su farmaci target-oriented in diversi modelli tumorali in vitro, quali: inibitori di EGFR, Sigma-2 agonisti, inibitori dei PPARs, inibitori di PARP-1, della Aurora B chinasi, ecc.
Gli studi sono focalizzati sull'analisi di inibizione della crescita cellulare, apoptosi, necrosi, autofagia etc. e l'indagine di tutti i meccanismi responsabili di questi fenomeni. esperienza nella caratterizzazione dei meccanismi di resistenza ai farmaci e sulle strategie terapeutiche per superarla e nella valutazione della stabilità chimico-fisica di farmaci chemioterapici.

PRODUZIONE SCIENTIFICA

1. Giannattasio, S., **Azzariti**, A., Marra, E. and Quagliariello, E. (1994) The N-terminal region of mature aspartate aminotransferase can direct cytosolic dihydrofolate reductase into mitochondria in vitro. Biochem. Biophys. Res. Commun. 201, 1059-1065.

2. Marra, E., **Azzariti**, A., Giannattasio, S., Doonan, S. and Quagliariello, E. (1995) Cumulative effects of mutations in newly-synthesised mitochondrial aspartate aminotransferase on uptake into mitochondria. Biochem. Biophys. Res. Commun. 214, 511-517.

3. **Azzariti**, A., Giannattasio, S., Doonan, S., Merafina, R.S., Marra, E. and Quagliariello, E. (1995) Use of protease sensitivity to probe the conformations of newly-synthesised mutant forms of mitochondrial aspartate aminotransferase and their abilities to bind to mitochondrial membrane proteins. Biochem. Biophys. Res. Commun. 215, 800-807.

4.**Azzariti**, A., Vacca, R.A., Giannattasio, S., Merafina, R.S., Marra, E., and Doonan, S. (1998) Kinetic properties and thermal stability of mutant forms of mitochondrial aspartate aminotransferase. Biochim. Biophys Acta 1386(1): 29-38.

5.Atlante, A., Calissano, P., Bobba, A., **Azzariti**, A., Marra, E., and Passerella, S.(2000) Cytochrome c is released from mitochondria in a reactive oxygen species (ROS)-dependent fashion and can operate as a ROS scavenger and as a respiratory substrate in cerebellar neurons undergoing excitotoxic death. J. Biol. Chem. 275 (47): 37159-37166.

6. Xu JM, **Azzariti** A, Tommasi S, Lacalamita R, Colucci G, Johnston PG, Church SW, Paradiso A. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance. Clin Colorectal Cancer. 2002 Nov;2(3):182-8

7. Xu JM, **Azzariti** A, Severino M, Lu B, Colucci G, Paradiso A. Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. Biochem Pharmacol. 2003 Aug 15;66(4):551-63

8.Xu JM, **Azzariti** A, Colucci G, Paradiso A. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines.Cancer Chemother Pharmacol. 2003 Dec;52(6):442-8

9. Bobba A, Atlante A, **Azzariti** A, Sgaramella G, Calissano P, Marra E. Mitochondrial impairment induces excitotoxic death in cerebellar granule cells. Int J Mol Med. 2004 Jun;13(6):873-6

10. **Azzariti** A., Xu JM., Porcelli L., and Paradiso A. (2002) The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa™, ZD1839). Biochem Pharmacol. 2004 68(1): 135-44

11. Giannelli G., **Azzariti** A., Fransvea E., Porcelli L., Antonaci S. and Paradiso A. Laminin-5 offsets Gefitinib's effectiveness on HCC cells Br J Cancer. 2004 Nov 29;91(11):1964-9

12. G Giannelli, A **Azzariti**, C Sgarra, L Porcelli, S Antonaci, A Paradiso ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells Biochemical Pharmacology 71 (2006) 479– 485

13. A. **Azzariti**, L. Porcelli, JM. Xu, GM. Simone, A. Paradiso. Prolonged exposure of colon cancer cells to the EGFR inhibitor gefitinib (Iressa™) and to the antiangiogenic agent ZD6474: cytotoxic and biomolecular effects. World J Gastroenterol. 2006 Aug

28;12(32):5140-7

14. A. **Azzariti**, NA. Colabufo, F. Berardi, L. Porcelli, M. Niso, GM. Simone, R. Perrone, A. Paradiso Cyclohexylpiperazine derivative PB28, a sigma-2 agonist and sigma-1 antagonist receptor activity, inhibits cell growth, modulates P-glycoprotein and synergizes with anthracyclines in breast cancer. Mol Cancer Ther. 2006 Jul;5(7):1807-16

15. Sebastian S., Settleman J., Reshkin SJ, **Azzariti** A., Paradiso A. The Complexity of Targeting EGFR Signalling in Cancer: From Expression to Turnover. Biochim Biophys Acta Reviews on Cancer. 2006 Aug;1766(1):120-39

16.Xu JM, Li YM, Wang Y, Zhao CH, Yuan SJ, Yang WW, Li ZQ, Han Y, **Azzariti** A, Paradiso A. [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan] Zhonghua Zhong Liu Za Zhi. 2006 Aug;28(8):578-82.

17. Cardone RA, Bellizzi A, Busco G, Weinman EJ, Dell'aquila ME, Casavola V, **Azzariti** A, Mangia A, Paradiso A, Reshkin SJ. The NHERF1 PDZ2 Domain Regulates PKA-RhoA-p38-mediated NHE1 Activation and Invasion in Breast Tumor Cells. Mol Biol Cell. 2007 May;18(5):1768-80

18. Prilla M., Calastretti A, Bruno P, **Azzariti** A, Paradiso A, Canti G, and Nicolin A. Preferential Chemosensitization of PTEN-Mutated Prostate Cells by Silencing the Akt Kinase. Prostate. 2007 May 15;67(7):782-9

19. Paradiso A, Mangia A, **Azzariti** A, Tommasi S. Phosphatidylinositol 3-kinase in breast cancer: where from here? Clin Cancer Res. 2007 Oct 15;13(20):5988-90. Review.

20. Bergamini C, Sgarra C, Trerotoli P, Lupo L, **Azzariti** A, Antonaci S, Giannelli G. Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha6beta4 and alpha3beta1 integrins. Hepatology. 2007 Dec;46(6):1801-9.

21. Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, **Azzariti** A, Simone GM, Porcelli L, Paradiso A. Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem. 2008 Jan 1;16(1):362-73.

22.**Azzariti** A, Porcelli L, Gatti G, Nicolin A, Paradiso A. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochem Pharmacol. 2008 Mar 1;75(5):1035-44.

23. Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, **Azzariti** A, Simone GM, Paradiso A. 4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators. Bioorg Med Chem. 2008 Apr 1;16(7):3732-43

24. Giannelli G, Sgarra C, Porcelli L, **Azzariti** A, Antonaci S, Paradiso A. EGFR and VEGFR as potential target for biological therapies in HCC cells. Cancer Lett. 2008 Apr 18;262(2):257-64.

25. Sebastian S, **Azzariti** A, Accardi R, Conti D, Pilato B, LaCalamita R, Porcelli L, Simone GM, Tommasi S, Tommasino M, Paradiso A. Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells. Int J Mol Med. 2008 Jun;21(6):809-17.

26. Xu JM, Han Y, Duan HQ, Gao EM, Zhang Y, Liu XQ, Zhang JS, Toschi L, Galetta D, **Azzariti** A, Paradiso A. EGFR mutations and HER2/3 protein expression and clinical outcome in Chines advanced non-small cell lung cancer patients treated with gefitinib. J Cancer Res Clin Oncol. 2009 Jun;135(6):771-82.

27.Porcelli L, Lemos C, Peters GJ, Paradiso A, **Azzariti** A. Intracellular Trafficking of MDR Transporters and Relevance of SNPs. Curr Top Med Chem. 2009;9(1):197-208.

28.**Azzariti** A, Porcelli L, Simone GM, Quatrale AE, Colabufo NA, Berardi F, Perrone

R, Zucchetti M, D'Incalci M, Xu JM, Paradiso A. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol. (2010) 65:335–346

29. Abate C, Elenewski J, Niso M, Berardi F, Colabufo NA, **Azzariti** A, Perrone R, Glennon RA. Interaction of the sigma(2) receptor ligand PB28 with the human nucleosome: computational and experimental probes of interaction with the H2A/H2B dimer. ChemMedChem. 2010 Feb 1;5(2):268-73

30. Sebastian S, **Azzariti** A, Silvestris N, Porcelli L., Russo A., Tommasino M and Paradiso A. Cell signalling network of cancerogenesis; p53 is the main traffic controller of the network. 2010 Frontiers in Biosciences Jun 1;15:1172-90.

31. E. Fransvea, A. Mazzocca, A. Santamato, A. **Azzariti**, S. Antonaci, G. Giannelli. Kinase activation profile associated with TGF-β dependent migration of HCC cells: a preclinical study. Cancer Chemotherapy and Pharmacology 2011 Jul;68(1):79-86.

32. N. Silvestris, E. Maiello, S. Cinieri, D. Santini, A. Russo, S. Tommasi, A. **Azzariti**, G. Numico, S. Pisconti, G. Colucci. Update on capecitabine alone and in combination regimens in colorectal cancer patients. Cancer Treatment Reviews. 2010 Nov;36S3:S46-S55

33. ME. Fratto, D. Santini, B. Vincenzi, N. Silvestris, A. **Azzariti**, S. Tommasi, A. Zoccoli, S. Galluzzo, E. Maiello, G.e Colucci, G. Tonini. Targeting EGFR in bilio-pancreatic and liver carcinoma. Front Biosci. 2011 Jan 1;3:16-22.

34. AE. Quatrale, D. Petriella, L. Porcelli, S. Tommasi, N. Silvestris, G. Colucci, A. Paradiso, A. **Azzariti**. Anti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidences. Front Biosci. 2011 Jan 1;16:1973-1985

35. AE. Quatrale, L. Porcelli, N. Silvestris, G. Colucci, A. Paradiso, A. **Azzariti**. Anti-EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidences. Front Biosci. 2011 Jan 1;16:1962-1972

36. NA. Colabufo, M. Contino, F. Berardi, R. Perrone, MA. Panaro, A. Cianciulli, V. Mitolo, A. **Azzariti**, AE. Quatrale, A. Paradiso. A new generation of MDR revertant agents with dual activity: P-gp inhibitor and iNOS inducer agents. Toxicol In Vitro. 2011 Feb;25(1):222-30

37. **Azzariti** A., Bocci G., Porcelli L., Fioravanti A., Sini P., Simone GM, Quatrale AE., Chiarappa P., Mangia A., Sebastian S., Del Bufalo D., Del Tacca M. and Paradiso A. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. Br J Cancer. 2011 Mar 1;104(5):769-80.

38. H. Calvert and A. **Azzariti**. Clinical development of PARP inhibitors. Ann Oncol. 2011 Jan;22 Suppl 1:i53-9.

39.**Azzariti** A., Porcelli L, Quatrale A.E., Silvestris N. and Paradiso A. The coordinated role of CYP450 enzymes and P-gp in determining cancer resistance to chemotherapy. Curr Drug Metab. 2011 Oct;12(8):713-21

40. Porcelli L, Assaraf YG, **Azzariti** A, Paradiso A, Jansen G, Peters GJ. The impact of folate status on the efficacy of colorectal cancer treatment. Curr Drug Metab. 2011 Dec;12(10):975-84.

41. Gnoni A, Russo A, Silvestris N, Maiello E, Vacca A, Marech I, Numico G, Paradiso A, Lorusso V, **Azzariti** A. Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients. Curr Drug Metab. 2011 Dec;12(10):918-31.

42. **Azzariti** A. Biomarkers of chemotherapeutics efficacy and toxicity in colorectal cancer. Curr Drug Metab. 2011 Dec;12(10):917.

43. Dituri F, Mazzocca A, Lupo L, Edling CE, **Azzariti** A, Antonaci S, Falasca M,

Giannelli G. PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma. Int J Cancer. 2012 Jun 1;130(11):2505-13.

44. **Azzariti** A, Quatrale AE, Porcelli L, Colabufo NA, Cantore M, Cassano G, Gasparre G, Iannelli G, Tommasi S, Panaro MA, Paradiso A. MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment. Eur J Pharmacol. 2011 Nov 16;670(1):74-84.

45. Porcelli L, Gilardi F, Laghezza A, Piemontese L, Mitro N, **Azzariti** A, Altieri F, Cervoni L, Fracchiolla G, Giudici M, Guerrini U, Lavecchia A, Montanari R, Di Giovanni C, Paradiso A, Pochetti G, Simone GM, Tortorella P, Crestani M, Loiodice F. Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity. J Med Chem. 2012 Jan 12;55(1):37-54.

46. Silvestris N, Del Re M, **Azzariti** A, Maiello E, Lombardi L, Cinieri S, Guarini A, Brunetti AE, Delcuratolo S, De Vita F, Pisconti S, Danesi R, Colucci G. Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S111-7.

48. Bellizzi A, Sebastian S, Ceglia P, Centonze M, Divella R, Manzillo EF, **Azzariti** A, Silvestris N, Montemurro S, Caliandro C, De Luca R, Cicero G, Rizzo S, Russo A, Quaranta M, Simone G, Paradiso A. Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis. J Cell Physiol. 2013 Feb;228(2):408-15.

49. Porcelli L, Quatrale AE, Mantuano P, Silvestris N, Brunetti AE, Calvert H, Paradiso A, **Azzariti** A. Synthetic lethality to overcome cancer drug resistance. Curr Med Chem. 2012;19(23):3858-73.

50. Porcelli L, Quatrale AE, Mantuano P, Silvestris N, Rolland JF, Biancolillo L, Paradiso A, **Azzariti** A. Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors. Curr Pharm Des. 2013;19(5):918-26.

51. Ribatti D, Ranieri G, Basile A, **Azzariti** A, Paradiso A, Vacca A. Tumor endothelial markers as a target in cancer. Expert Opin Ther Targets. 2012 Dec;16(12):1215-25.

52. Porcelli L, Quatrale AE, Mantuano P, Leo MG, Silvestris N, Rolland JF, Carioggia E, Lioce M, Paradiso A, **Azzariti** A. Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol. 2013 Jun;7(3):308-22.

53. Pagliarulo V, Ancona P, Niso M, Colabufo NA, Contino M, Cormio L, **Azzariti** A, Pagliarulo A. The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line. Mol Cancer. 2013 May 24;12:47.

54. Silvestris N, Gnoni A, Brunetti AE, Vincenti L, Santini D, Tonini G, Merchionne F, Maiello E, Lorusso V, Nardulli P, **Azzariti** A, Reni M. Target Therapies In Pancreatic Carcinoma. Curr Med Chem. 2013 Aug 23. [Epub ahead of print]

55. Quatrale AE, Porcelli L, Gnoni A, Numico G, Paradiso A, **Azzariti** A. New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies. Curr Med Chem. 2013 Aug 23. [Epub ahead of print]

56. **Azzariti** A. Editorial "Targeted Therapies in Upper Gastrointestinal Malignancies." Curr Med Chem. 2013 Aug 23. [Epub ahead of print].

57. Gnoni A, Licchetta A, Scarpa A, **Azzariti** A, Brunetti AE, Simone G, Nardulli P, Santini D, Aieta M, Delcuratolo S, Silvestris N. Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. Int J Mol Sci. 2013 Sep 30;14(10):19731-62.

58. Niso M, Abate C, Contino M, Ferorelli S, **Azzariti** A, Perrone R, Colabufo NA, Berardi F. Sigma-2 receptor agonists as possible antitumor agents in resistant tumors: hints for collateral sensitivity. ChemMedChem. 2013 Dec;8(12):2026-35.

59. Silvestris N, Pantano F, Ibrahim T, Gamucci T, De Vita F, Di Palma T, Pedrazzoli P,

Barni S, Bernardo A, Febbraro A, Satolli MA, Bertocchi P, Catalano V, Giommoni E, Comandone A, Maiello E, Riccardi F, Ferrara R, Trogu A, Berardi R, Leo S, Bertolini A, Angelini F, Cinieri S, Russo A, Pisconti S, Brunetti AE, **Azzariti** A, Santini D. Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. PLoS One. 2013 Oct 28;8(10):e74402.